Merck plans to stop a late-stage study testing its drug to treat pulmonary arterial hypertension (PAH) ahead of time based on ...

We recently compiled a list of the Jim Cramer Discussed These 12 Stocks Amidst The DeepSeek AI Selloff. In this article, we ...

All patients in the trial will have the opportunity to resume or begin treatment with Winrevair, the company said.

Merck said the Phase 3 "Hyperion" study, which was evaluating Winrevair versus placebo in recently diagnosed adults with PAH at intermediate or high risk of disease progression, had lost clinical ...

Merck & Co Inc (MRK) stock saw a modest uptick, ending the day at $98.28 which represents a slight increase of $0.83 or 0.85% from the prior close of $97.45. The stock opened at $97.42 and touched a ...

The Phase III HYPERION trial was stopped early after strong positive interim results from the ZENITH trial demonstrated the efficacy of Winrevair (sotatercept-csrk) in treating pulmonary arterial ...

Bank of America Securities analyst Tim Anderson reiterated a Buy rating on Merck & Company (MRK – Research Report) today and set a price ...

Merck must face trial on a Black IT director’s claims that racial bias drove his firing after he ordered the removal of a White contractor from a project, a New York federal judge ruled.

Disclosed in the latest SEC filing, a significant insider purchase on January 29, involves Chirfi Guindo, Chief Marketing Officer at Merck & Co MRK.

What Happened: In a recent Form 4 filing with the U.S. Securities and Exchange Commission on Wednesday, Oosthuizen increased their investment in Merck & Co by purchasing 8,664 shares through ...

Merck's blockbuster drug Keytruda and Eisai's cancer drug Lenvima, in combination with chemotherapy, failed to improve ...

Merck and Japan-based Eisai said on Friday a combination of their therapies failed to extend the lives of patients with a ...